Publications by authors named "E J Teufel"
Article Synopsis
- Belantamab mafodotin is an innovative drug approved for treating multiple myeloma patients who have not responded to other therapies, providing an alternative for those who can't use CAR-T or bispecific antibodies.
- The drug's unique ocular side effects, like corneal microcysts and keratopathy, pose challenges for broader usage, and the study identifies a possible mechanism through which the drug affects the eyes via soluble BCMA (sBCMA) in tear fluid.
- Results show that inhibiting the uptake of sBCMA could prevent keratopathy, suggesting that future treatment strategies might involve using different therapies before administering belantamab or combining it with gamma-secretase inhibitors in ongoing research.
The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms, resulting in improved response rates. Nevertheless, patients continue to relapse and the underlying mechanisms of resistance remain poorly understood.
View Article and Find Full Text PDFWe analyzed single nucleotide polymorphisms (SNPs) in PKNOX1 (rs2839629) and in the intergenic region between PKNOX1 and CBS (rs915854) by Sanger sequencing in 88 patients with multiple myeloma treated with bortezomib. All patients (n = 13) harboring a homozygous mutation in PKNOX1 (rs2839629) also had a homozygous mutated rs915854 genotype. Homozygous mutated genotypes of rs2839629 and rs915854 were significantly enriched in patients with painful peripheral neuropathy (PNP) (P < 0.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to compare the effects of low-dose (20/27 mg/m²) and high-dose (≥36 mg/m²) carfilzomib on proteasome inhibition in patients with relapsed/refractory multiple myeloma.
- Results revealed that high-dose carfilzomib significantly inhibited the β2 and β1 proteasome subunits, leading to better overall response rates and longer progression-free survival compared to low-dose treatments.
- The findings suggest that an optimal dosing of carfilzomib should be at least 36 mg/m² to enhance anti-tumor activity, while also taking into consideration individual patient tolerance.